News

The prospective double-blind controlled multicenter trial randomized hospitalized adult patients with hospital-acquired or healthcare-associated MRSA pneumonia to receive intravenous Linezolid (600 mg every 12 hours) or Vancomycin (15

Waters will make use of the technologies from both companies to combine into a single, fully-supported analytical system solution that helps laboratories increase assay throughput and efficiency, improve

Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor, and is licensed from Mitsubishi Tanabe Pharma. The randomized double-blind placebo-controlled Revive (TA-301) trial of Avanafil enrolled 646

The initial phase of the contract is believed to be worth $15m. Paragon will develop a large-scale process suitable for cGMP manufacturing, under the contract. Previously in October

The compound which is a DNA minor groove binder is currently in pre-clinical development with IND filing targeted for the third quarter of 2012. Almac Operations VP Rick

The FDA-approved Soltamox is used primarily for the chronic treatment of breast cancer or for prevention in certain susceptible breast cancer subgroups. Under the terms of the merger

Voraxaze is used to treat toxic plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function. The approval of Voraxaze was granted under priority

Antares oxybutynin gel 3% is a topical, translucent hydroalcoholic gel containing oxybutynin, an antispasmodic, antimuscarinic agent and is indicated for the treatment of (OAB). The FDA approved oxybutynin

CDX-301 is soluble, recombinant human FMS-like tyrosine kinase 3 ligand (Flt3L) that stimulates the expansion and differentiation of hematopoietic progenitor and stem cells. The dose-escalating Phase 1 study